Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma, based in Cambridge, Massachusetts, announced a conference call on March 16, 2021, at 4:30 p.m. EDT, to provide a business update. The call will cover updates on the CUE-101 Phase 1 dose escalation trial and the KEYNOTE-A78 combination trial with KEYTRUDA for HPV+ recurrent head and neck cancer. Additionally, the management will discuss pipeline developments and strategic milestones. Investors can join via phone or webcast, with details available on the company’s website.

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Tuesday, March 16, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.

Members of the Cue Biopharma executive management team will provide clinical updates on the Company’s ongoing CUE-101 Phase 1 dose escalation monotherapy trial, which will include new patient data, and on the combination trial KEYNOTE-A78, where CUE-101 will be evaluated in combination with KEYTRUDA^® (pembrolizumab) as first-line treatment for HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Management will also provide an update on the Company’s most recent technology platform developments and pipeline progress as well as updates on its strategic objectives and anticipated milestones.

Tuesday, March 16 at 4:30 p.m. EDT

Investors:	877-407-9208
International:	201-493-6784
Conference ID:	13716744
Webcast:	http://public.viavid.com/index.php?id=143645

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.

Investor Contact
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
gzavoico@cuebio.com

Media Contact
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com

FAQ

What is the date and time of Cue Biopharma's conference call in March 2021?

Cue Biopharma's conference call is scheduled for March 16, 2021, at 4:30 p.m. EDT.

What updates will Cue Biopharma provide during the conference call?

Cue Biopharma will provide updates on the CUE-101 Phase 1 trial and the KEYNOTE-A78 combination trial with KEYTRUDA.

How can I access Cue Biopharma's conference call and webcast?

The conference call and webcast can be accessed via Cue Biopharma's website.

What is the focus of Cue Biopharma's ongoing clinical trials?

Cue Biopharma's ongoing trials focus on HPV+ recurrent/metastatic head and neck squamous cell carcinoma.

What is the significance of the Immuno-STAT platform developed by Cue Biopharma?

The Immuno-STAT platform is designed to engage and modulate T cells directly within the patient's body, transforming cancer treatment.